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Can Regulation be as Innovative as Science and
Technology? The FDA’s Regulation of
Combination Products
Susan Bartlett Foote∗ & Robert J. Berlin∗∗
INTRODUCTION
The twentieth century witnessed significant and
continuous advances in medical product innovation, with
breakthroughs in pharmaceutical, engineering and bioscience
fields that revolutionized health care services. However, with
innovation comes potential risk. Congress has been concerned
about risks associated with medical products since the early
1900s,1 and has, over time, empowered the U.S. Food and Drug
Administration (FDA) to ensure that new medical products
meet evolving standards of safety and effectiveness. The Food,
Drug, and Cosmetic Act (FDCA) has been amended numerous
times since the early 1900s, often in reaction to both perceived
and real risks associated with new medical products.2 The
result is a complex regulatory apparatus that administers a
variety of legislative mandates specifically tailored to the
unique features of drugs, medical devices and biologics.
In recent years, scientific and technological advances in the
fields of tissue engineering, cell biology, gene therapy and
materials science, to name a few, promise breakthroughs that
∗ J.D., M.A. Associate Professor, Division of Health Services Research
and Policy, University of Minnesota, School of Public Health.
∗∗ J.D., MPH (Epidemiology), expected 2007, Joint Degree Program in
Law, Health & Life Sciences, University of Minnesota.
1. See Biologics Act of 1902, ch. 1378, 32 Stat. 728 (1902) (codified as
amended at 42 U.S.C. § 262 (2000)). Pure Food and Drug Act of 1906, Pub. L.
No. 59-384, 34 Stat. 768, 768-70 (1906) (repealed 1938).
2. E.g., Safe Medical Devices Act of 1990, Pub. L. No. 101-629, § 16, 104
Stat. 4511, 4526 (1990) (current version at 21 U.S.C. § 353(g) (2000)); Food
and Drug Administration Modernization Act of 1997, Pub. L. No. 105-115, 111
Stat. 2296 (1997) (current version at 21 U.S.C. § 301 (2000)); Medical Device
Amendments of 1976, Pub L. No. 94-295, 90 Stat. 539, 540-42 (1976) (current
version at 21 U.S.C. §§ 360c-360k (2000)).
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no longer fit the clear statutory distinctions among drugs,
medical devices, or biologics.
These products, known as
“combinations” because they mix attributes of drugs, biologics,
or medical devices, challenge the FDA to adapt its regulatory
schema to these novel combinations.3
The purpose of this article is threefold. First, we provide
an overview of the innovation pipeline of combination products
to illustrate the depth and breadth of the potential
contributions of this field. Second, we summarize the evolution
of the FDA over the last one hundred years and evaluate its
initial efforts since 1990 to accommodate combination products.
We find that the combination product provisions in statute and
regulation follow a sequence that includes: a focus on
definitions to distinguish between types of products as they
emerge, a willingness by the FDA to stretch the limits of the
definitions as new products evolve, and congressional
intervention, often in reaction to crises or external pressures, to
revise old definitions to reflect changes in product types. Third,
we discuss why the traditional response to innovation may be
ill-suited to the accelerated pace of the combination product
revolution. We evaluate the likely responses of Congress, the
FDA, and the regulated entities to possible changes in the
approach to combination product regulation. We hope that our
analysis will add to the understanding of the current
regulatory environment and inform the on-going policy debate.
I. OVERVIEW OF SCIENCE AND TECHNOLOGY OF
COMBINATION PRODUCTS
We are now in an era of tremendous innovation in medical
products that promises to transform medicine as we know it.
This era is also characterized by new forms of innovation. In
the twentieth century, there were major advancements in the
fields of pharmaceuticals, engineered devices, and biologics. A
new generation of products, however, combines attributes of
these three formerly distinct fields. While it is impossible to
predict with accuracy the next generation of medical product
advances, it is clear that many will take the form of
combination products.
The
earliest
combinations
involved
adding
a
3. See, e.g., Definition of Primary Mode of Action of a Combination
Product, 69 Fed. Reg. 25,527, 25,528-30 (proposed May 7, 2004) (to be codified
at 21 C.F.R. pt. 3).
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pharmaceutical agent to a therapeutic device, such as putting a
steroid drug on a pacemaker electrode to speed healing and
reduce scarring.4 The recently introduced drug-eluting stents
fall into this drug-device combination category.5
Tissue engineering and tissue replacement is a burgeoning
area of growth that involves various combinations of biologics,
devices, and drugs. Scientists have found that matrix scaffolds
can serve as a mechanical substrate for regeneration of
cartilage.6 Adding components, such as growth factors, cells, or
nutrients, hasten the growth of new tissue. There are many
applications and potential uses for tissue engineered products,
including tissue substitutes for burns, ulcers and
reconstruction to the development of structural tissue products,
organs, and organ systems.7
Another growth area for combination product research is in
the field of gene therapy. Cells must be targeted for the
delivery of modified gene sequences. Delivery mechanisms may
include viruses (a biologic)8 or synthetics, such as natural or
synthetic lipids or purely synthetic polymers (a device).9 Other
drug delivery mechanisms may be device-like in nature, such
as leads to thread through the venous system to targeted
organs or sites within the body.
Nanomedicine is the monitoring, repair, construction and,
4. See John Carey, Combo Medicine, BUSINESSWEEK, Mar. 25, 2003,
available at http://www.keepmedia.com/pubs/businessweek/2003/03/25/18043.
5. See id.
6. Lichun Lu, et al., Biodegradable Polymer Scaffolds for Cartilage
Tissue Engineering, CLINICAL ORTHOPEDICS & RELATED RES, Oct. 2001, at
S251-252, available at http://gateway.ut.ovid.com/gw2/ovidweb.cgi.
7. See Amy J. LaForte, Bone Morphogenetic Protein Combination
Products and Orthopedic Repair, in NAT’L RESEARCH COUNCIL, PROCEEDINGS
FROM THE WORKSHOP ON SCIENCE-BASED ASSESSMENT: ACCELERATING
PRODUCT DEVELOPMENT OF COMBINATION MEDICAL DEVICES 15 (Bonnie A.
Scarborough ed., 2004) [hereinafter NAT’L RESEARCH COUNCIL]; William
McKay, Product Development Process for a Bone Morphogenetic Protein
Combination Product, in NAT’L RESEARCH COUNCIL, supra, at 15 ; Robert S.
Schwartz, Drug-Eluting Stents, in NAT’L RESEARCH COUNCIL, supra, at 18; H.
Semih Oktay, Drug-Eluting Stents: Preclinical Testing Challenges, in NAT’L
RESEARCH COUNCIL, supra, at 19; Ronald A. Sahatjian, Taxus: A PolymerBased Paclitaxel-Eluting Stent, in NAT’L RESEARCH COUNCIL, supra, at 20.
8. Lonnie D. Shea & Tiffany L. Houchin, Modular Design of Non-viral
Vectors with Bioactive Components, 22 TRENDS IN BIOTECHNOLOGY 429, 429
(2004).
9. Tristan Montier et al., Non-viral Vectors in Cystic Fibrosis Gene
Therapy: Progress and Challenges, 22 TRENDS IN BIOTECHNOLOGY 586, 587
(2004).
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control of human biological systems at the molecular level,
using engineered nanodevices and nanostructures. Promising
novel combinations in the nanotechnology pipeline include
nanorobots that can travel through the body to find illness and
target
the
delivery
of
drugs
and
biologics.10
Microelectromechanical systems (MEMS) devices are tiny
mechanical and electrical elements integrated onto a silicon
chip to perform functions such as sensing. These compact
devices with sophisticated functionality have many potential
biomedical uses, including precision drug delivery using
integrated microvalves and pumps, and portable biochemical
analysis instrumentation using microfluidic networks. 11
Some of these innovations have already come to the
market, but many of them are in the research and development
phase. The FDA has reviewed several hundred combinationtype products since the term was statutorily defined; data now
compiled by the agency shows that there were approximately
sixty-one requests for designation (RFD) as combination
products between October 1, 2003 and September 30, 2004.12
The innovative scientists and engineers in these and
related fields face many challenges in the development of these
products. But they will all have to navigate through the FDA
process. Can regulation be as innovative as science and
technology?
II. HISTORY OF REGULATORY EVOLUTION
The over one hundred years of U.S. regulation of medical
products provides a rich narrative history reflecting a cycle of
scientific innovation and regulatory response.
There are
numerous extensive analyses of this history, which we
commend to the interested reader.13 The purpose of our
10. See John Miller, Beyond Biotechnology: FDA Regulation of
Nanomedicine, 4 COLUM. SCI. & TECH. L. REV. 1-2 (2003).
11. See Yvonne Carts-Powell, Developing MEMS for Medicine, 200 OE
REPORTS,
Aug.
2000,
at
http://www.spie.org/web/oer/august/aug00/stanford.html (last visited Nov. 7,
2004).
12. OFFICE OF COMBINATION PRODS., U.S. FOOD AND DRUG ADMIN., FY04
OCP
REVIEW
PERFORMANCE,
at
http://www.fda.gov/oc/combination/fy04rfd.html (last visited Nov. 7, 2004).
Thirty-four of the sixty-one products for which designation was requested were
categorized as combination products between October 2003 and September
2004. Id.
13. See generally SUSAN BARTLETT FOOTE, MANAGING THE MEDICAL
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cursory overview is to describe how policy adapted to new
products. When a new type of product is considered as a target
for regulation, there has often been a focus on classification of
the product type through detailed definitions. “Definitional
controversies are an established feature of food and drug law,
driven by the differential treatment of the various categories of
FDA-regulated products.”14 The agency has tended to try to
stretch its authority to clarify gray areas as new product types
emerge.
There often has been a congressional reaction,
triggered by external crises or pressure, to revisit the
definitions and amend FDA authority.
The result is a
patchwork of legislative mandates and a silo effect, with
differently defined products being regulated differently. The
following discussion elucidates this pattern for the three
medical product categories—drugs, medical devices, and
biologics.15
A. EARLY DRUG AND DEVICE REGULATION
Public concern about fraud in the sale of food and medicine
grew during the 1880s and 1890s in response to diseased or
adulterated foodstuffs. Because there were few effective drugs
at this time, and most were not purchased directly through
medical doctors, drugs were seen as part of food regulation.
Many nostrums and medicines contained dangerous habitforming narcotics.16 Harvey W. Wiley, Chief of the Division of
Chemistry at the Department of Agriculture, became a

ARMS RACE: INNOVATION AND PUBLIC POLICY IN THE MEDICAL DEVICE
INDUSTRY (Univ. of Cal. Press, 1992); PETER BARTON HUTT & RICHARD A.
MERRILL, FOOD AND DRUG LAW: CASES AND MATERIALS (2d. ed. 1991);
CHARLES O. JACKSON, FOOD AND DRUG LEGISLATION IN THE NEW DEAL
(1970); Susan Bartlett Foote, Loops and Loopholes: Hazardous Device
Regulation Under the 1976 Medical Device Amendments to the Food, Drug and
Cosmetic Act, 7 ECOLOGY L.Q. 101 (1978); Henry G. Grabowski & John M.
Verson, Consumer Protection Regulation in Ethical Drugs, 67 AM. ECON. REV.
359 (1977); Peter Barton Hutt, A History of Government Regulation of
Adulteration and Misbranding of Medical Devices, 44 FOOD DRUG COSM. L.J.
99 (1989); Vincent A. Kleinfeld, Legislative History of the Federal Food, Drug,
and Cosmetic Act, 1 FOOD DRUG COSM. L.Q. 532 (1946); Symposium, The New
Food, Drug, and Cosmetic Legislation, 6 LAW & CONTEMP. PROBS. 1 (1939).
14. Linda R. Horton, Over-the-Counter Drug Authority Issues: Selected
Topics, 48 FOOD & DRUG L.J. 545, 551 (1993).
15. While the FDA also has regulatory power over foods, we restrict this
analysis to drugs, biologics and devices.
16. Oscar E. Anderson, Pioneer Statute: The Pure Food and Drugs Act of
1906, 13 J. PUB. L. 189, 189 (1964).
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missionary for reform.17 The publication of Upton Sinclair’s
The Jungle in 1905, with its graphic images of adulterated food,
aroused the public to demand reform.
After years of unsuccessful efforts, the first major federal
initiative was the Pure Food and Drugs Act of 1906.18The law
defined drugs as separate from food, and extended the
definition to include not only medicines recognized by the
United States Pharmacopoeia (USP), but also any substance
intended for the cure, mitigation, or treatment of disease,
bringing proprietary medicines within the scope of the law.19
The law conferred limited authority, allowing the federal
government the authority to seize adulterated or misbranded
articles on the market. The Department of Agriculture,
Division of Chemistry, was charged with enforcing the new law.
Enforcement activities against adulterated foods and drugs
increased throughout the 1920s. By 1931, the FDA had been
established within the Department of Agriculture. Officials
were severely handicapped in reaching the adulterated
products because of the limitations of the seizure authority.20
The new Roosevelt Administration supported expanding federal
authority in 1933, although it took over five years of effort to
enact reforms.21
In the debates leading up to the subsequent legislation,
there was reference, for the first time, to medical devices. An
FDA report in 1933 stated:
Mechanical devices, represented as helpful in the cure of disease, may
be harmful. Many of them serve a useful and definite purpose. The
weak and ailing furnish a fertile field, however, for mechanical
devices represented as potent in the treatment of many conditions for
which there is no effective mechanical cure. The need for legal control

17. OSCAR E. ANDERSON, THE HEALTH OF A NATION: HARVEY W. WILEY
AND THE FIGHT FOR PURE FOOD 1-16 (University of Chicago Press, 1958).
18. Pure Food and Drug Act of 1906, Pub. L. No. 59-384, 34 Stat. 768, 76872 (1906) (repealed 1938).
19. Since 1820, the USP has set standards for medications used by the
American public. It is an independent, nonprofit corporation composed of
delegates with expertise in medicine. The 1906 law recognized the USP
standards. Proprietary drugs are those sold directly to the public, and they
include patent medicines. The term proprietary indicates that the ingredients
are secret, not that they are patented. See generally USP Website, at
http://www.usp.org/ (last visited Apr. 22, 2005).
20. David F. Cavers, The Food, Drug and Cosmetic Act of 1938: Its
Legislative History and Its Substantive Provisions, 6 LAW & CONTEMP. PROBS.
2, 15-16 (1939).
21. See id. at 2, 3 n.9.
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of devices of this type is self-evident . . . . The new statute, if enacted,
will bring such products under the jurisdiction of the law.22

There was heated Congressional debate over how to define
drugs and devices. An early Senate bill would have defined
drugs to include all substances, preparations and devices
“intended for use in the cure, mitigation, treatment or
prevention of disease.”23 When this language was debated in
the Senate, there was no objection to regulation of devices, but
instead controversy about defining them as drugs. One Senator
argued that to treat devices as drugs “in law and in logic and in
lexicography is a palpable absurdity.”24
The bill addressing concerns about drug and device
authority languished in Congress until a drug disaster focused
public attention. The Massengill Company produced a liquid
form of sulfanilamide, one of the new classes of sulfa drugs on
the market. The solution was toxic and one hundred people
died after ingesting the elixir.25
The resulting legislation responded to the public pressure
for reform, and set drugs and devices on different pathways
from a regulatory perspective. The 1938 law specifically
defined “new drugs” as distinct from drugs, and expanded the
FDA’s power over them.26 For the first time, the agency could
subject “new drugs” to pre-market controls, rather than just the
authority to seize misbranded or adulterated products.27 The
legislation also defined medical devices for the first time.28
However, by definition they were not “new drugs” so the premarket authority did not apply.29 Medical devices were now
22. U.S. DEP’T OF AGRIC., REPORT OF THE CHIEF OF THE FOOD AND DRUG
ADMINISTRATION, 13-14 (1933).
23. S. REP. NO. 493, at 2 (1934).
24. Bruce C. Davidson, Preventive “Medicine” for Medical Devices: Is
Further Regulation Required?, 55 MARQ. L. REV. 405, 415 (1972) (quoting
Senator Clark).
25. See Foote, Loops and Loopholes, supra note 13, at 106.
26. See Cavers, supra note 20, at 32-33, 40.
27. See id.
28. See id.
29. The definitions are as follows:
The term “drug” means (A) articles recognized in the official United
States Pharmacopoeia, official Homoeopathic Pharmacopoeia of the
United States, or official National Formulary, or any supplement to
any of them; and (B) articles intended for use in the diagnosis, cure,
mitigation, treatment, or prevention of disease in man or other
animals; and (C) articles (other than food) intended to affect the
structure or any function of the body of man or other animals; and (D)
articles intended for use as a component of any article specified in
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subject to regulation, but only to the provisions referring to
adulteration and misbranding of products already on the
market.30
The pattern of careful definition of products by category
and tailoring regulatory authority to these definitional
distinctions emerged. It was also clear that external pressure,
often in the form of crises of some kind, helped to stir Congress
into action.
Another tragedy spurred major new drug legislation in
1962. In the 1950s, thalidomide, a sedative, was approved in
Europe.31 Hundreds of pregnant women who took the drug
gave birth to children with serious deformities.32 Although the
drug was only approved for limited distribution in the United
States, news of the link between thalidomide and the deformed
children in Europe facilitated the passage of amendments to
the FDCA that were pending at the time.33 Under the 1962
amendments, requirements for pre-market drug approvals
increased to include a finding of efficacy as well as safety.34
These amendments put additional distance between the drug
and the device authorities.

clause (A), (B), or (C).
21 U.S.C. § 321(g)(1)(2000).
The term “device” (except when used in paragraph (n) of this section
and in sections 331(i), 343(f), 352(c), and 362(c) of this title) means an
instrument, apparatus, implement, machine, contrivance, implant, in
vitro reagent, or other similar or related article, including any
component, part, or accessory, which is -- (1) recognized in the official
National Formulary, or the United States Pharmacopoeia, or any
supplement to them, (2) intended for the use in the diagnosis of
disease or other conditions, or in the cure, mitigation, treatment, or
prevention of disease, in man or other animals, or (3) intended to
affect the structure of any function of the body of man or other
animals, and which does not achieve its primary intended purposes
through chemical action within or on the body of man or other
animals and which is not dependent upon being metabolized for the
achievement of its primary intended purposes.
Id. § 321(h) (2000).
30. See Cavers, supra note 20, at 31-37.
31. HARVEY TEFF & COLIN MUNRO, THALIDOMIDE: THE LEGAL
AFTERMATH 1 (Saxon House, 1976).
32. Id. at 4-5.
33. Id. at 118-24.
34. Id. at 123.
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B. DEVICE REGULATION EXPANDS
Throughout the 1950s and 1960s, the medical device
industry grew in size and the products grew in complexity.
Examples include monitoring equipment in coronary care units,
automated laboratory equipment, new implanted devices such
as pacemakers, and a myriad of diagnostic and therapeutic
instruments.35 During this period, the Bureau of Drugs
continued to enforce both the drug and device provisions.
Confronted with inadequate regulatory powers of the more
complex medical devices, the FDA tried to stretch the limits of
its authority by classifying some devices as drugs under the
1962 law. In 1968, the Second Circuit upheld the FDA’s
classification of a nylon ligature loop and nylon locking disk
used to tie off severed blood vessels during surgery as a drug.
In AMP v. Gardner,36 the court broadly construed the definition
of drug by emphasizing the public health goals of the law,
holding that a medical product not generally recognized as safe
and effective could be termed a “drug” and regulated as such.37
In the next year, the Supreme Court also broadly construed the
term “drug” to apply to an antibiotic disk in United States v. An
Article of Drug . . . Bacto-Unidisk. . . .38 In Bacto-Unidisk, the
Court concluded that the term “drug” was a legal term of art
which could be “given a liberal construction consistent with the
[FDCA’s] overriding purpose to protect the public health.”39
There was growing legislative interest in expanding
medical device regulation during the 1960s as recognition of
the problems grew. Court decisions had confused the situation
for manufacturers who were uncertain about how their
Bills to expand device
products would be regulated.40
regulation had been introduced during both the Johnson and
Nixon Administrations.41 In 1969, the Department of Health,
Education, and Welfare (HEW), of which the FDA was a part,
convened a study group to investigate the need for additional
legislation. Named the Cooper Committee, after Chairman Dr.
35. Theodore Cooper, Device Legislation, 26 FOOD DRUG COSM. L.J. 165,
166 (1971).
36. 389 F.2d 825 (2d Cir. 1968).
37. Id. at 829-31.
38. 394 U.S. 784 (1969).
39. Id. at 798.
40. Vincent A. Kleinfeld, Sterile Disposable and Other Therapeutic Devices
and the Law, 27 FOOD DRUG COSM. L.J. 19, 21 (1972).
41. See Cooper, supra note 35, at 169.
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Theodore Cooper, the group advocated new legislation,
including a system to classify devices based on risk.
Seven years elapsed between the report of the Cooper
Committee and the passage of the Medical Device Amendments
(MDA) in 1976. During that time, numerous bills were
proposed and debated. The controversies over intrauterine
devices (IUDs) and extensive pacemaker recalls in the midseventies42 stimulated public concern and legislative interest,
much as the Elixir-Sulfanilamide disasters in 1938 and the
thalidomide tragedy in 1962.43 The FDA began to position
itself for potential legislation. In 1971, the Office of Medical
Devices was transferred from the Bureau of Drugs to the Office
of the Associate Commissioner for Medical Affairs.44 Three
years later, in 1974, responsibility for regulating devices was
vested in a new Bureau of Medical Devices and Diagnostic
Products, later renamed the Bureau of Medical Devices
(BMD).45
The MDA stepped up the regulatory authority over devices
by providing “reasonable assurance of safety and effectiveness”
for all devices.46 Devices on the market the day the law passed
included pre-1976 devices and devices later introduced which
are similar or substantially equivalent to them, often called
510(k)s after the section of the legislation which regulates
them. The new law distinguished between pre-1976 devices
and devices first developed after the date the law passed.
Congress described a classification scheme based on risk
because of the variety of devices, ranging from simple tongue
depressors to implantable cardiac pacemakers. Class I devices
consist of those generally considered to present no risks, Class
II devices are those whose characteristics are well known so
42. See DEP’T OF HEALTH, EDUC., AND WELFARE, FOOD AND DRUG
ADMINISTRATION’S INVESTIGATION OF DEFECTIVE CARDIAC PACEMAKERS
RECALLED BY THE GENERAL ELECTRIC COMPANY 21 (1975); see generally
Regulation of Medical Devices (Intrauterine Contraceptive Devices): Hearings
Before the Subcomm. on Intergovernmental Relations of the House Committee
on Government Operations, 93rd Cong. (1973).
43. Foote, Loops and Loopholes, supra note 13, at 110-11.
44. Richard A. Merrill, The Architecture of Government Regulation of
Medical Products, 82 VA. L. REV. 1753, 1803-04, n.157 (1996) (citing Peter
Barton Hutt, A History of Government Regulation of Adulteration &
Misbranding of Medical Devices, 44 Food Drug. Cosm. L.J. 99, 110-11 (1989).
45. Id. The current name of the device authority is the Center for Devices
& Radiological Health (CDRH).
46. Medical Device Amendments of 1976, Pub L. No. 94-295, 90 Stat 539,
541 (1976) (current version at 21 U.S.C. §§ 360c-360k (2000)).
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that safety and efficacy can be guaranteed through
performance standards, and Class III devices are those whose
safety and effectiveness are sufficiently uncertain that they
cannot be determined without additional testing. Only Class
III devices must meet pre-market approval requirements
equivalent to new drugs. The law created a variety of
regulatory pathways for medical devices, depending on how
they were classified, when they were marketed, and their
“equivalence” to products on the market when the law was
passed.
Some have argued that Congress had hoped that its
revision of the device definitions would end the issue of
whether a particular product was a drug or a device. However,
there were no mechanisms to resolve disputes in close cases.
“Accordingly, there was a tendency . . . for the FDA to rule that
a particular product was a drug rather than a device,”
particularly if there was a combination of a drug and a device.
The FDA took the position that although devices, as a matter of
law, may not have those mechanisms of actions, there is
nothing in the drug definition that restricts it to articles
employing those mechanisms of action.47
From 1906 until the 1980s, Congress periodically expanded
the FDA’s regulatory authority. It did so through discrete
legislation that focused on detailed definitions of new products,
such as drugs, new drugs, devices, discrete classifications of
devices, and so on. The regulatory requirements followed the
definitional categories. When regulatory authority did not fit
the risks as defined by the FDA, the agency tended to stretch
the confines of the law to accommodate its regulatory
preferences. During this period, regulatory silos emerged to
implement these very different legislative regimes. The drug
regulation was administered by the Center for Drug Evaluation
and Research (CDER); the Center for Devices and Radiological
Health (CDRH) managed devices.
C. BIOLOGICS REGULATION
At this point in our narrative, it is important to turn
attention to the evolution of the regulation of biologics.
47. Rodney R. Munsey, Trends and Events in FDA Regulation of Medical
Devices Over the Last Fifty Years, 50 Food & Drug L.J. 163, 169 n.30. (1995)
(citing a letter from William Randolph, Acting Associate Commissioner for
Regulatory Affairs to Luster J. Lifton in response to an inquiry regarding the
regulatory status of a saline solution).
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Biologics followed a parallel but separate track from drugs and
devices. The Biologics Act passed in 1902 in response to
tetanus-causing microbes’ contamination of batches of smallpox
vaccine and diphtheria antitoxin. Biologics were defined as
“any virus, therapeutic serum, toxin, antitoxin, or analogous
product applicable to the prevention and cure of disease of
man.”48 Chronologically, it was the first significant attempt to
regulate medical technology, but its importance was obscured
by the passage four years later of the Pure Food and Drugs Act
of 1906.
The focus of early biologics regulation was to prevent
contamination during the manufacturing process, which was
appropriate to the era when biologics were crude mixtures or
biological extracts.49 The law required that a manufacturer
obtain a license for its biologic product, properly label the
product and submit to inspection of its facilities. The initial
authority to regulate was at the Treasury Department. The
regulatory power was transferred to the Hygienic Laboratory in
1903, which later became the National Institutes of Health.50
Biologics were clearly distinguished from categories of
drugs, relatively simple molecules that are chemically
synthesized or extracted from plant and other sources of very
high level of purity. However, despite the fact that the
regulatory scheme, the responsible authority, and the products
themselves differed from drugs, there were gray areas between
these two categories. The FDA assumed jurisdiction over
insulin in 1941 and antibiotics in 1945, despite the fact that
“[b]oth products, and insulin in particular, had more in
common with biologics than they did with pharmacological
preparations.”51
The Biologics Act was revised in 1944 as part of the Public
Health Service Act52 which added mandatory product licensure
and specified the criteria for issuing license approvals.
Additional changes occurred in biologics regulation in response
to what was known as the “Cutter incident,” when a number of
48. Biologics Act of 1902, ch. 1378, 32 Stat. 728, (1902) (current version at
42 U.S.C. § 262 (2000)).
49. Gary E. Gamerman, Regulation of Biologics Manufacturing:
Questioning the Premise, 49 FOOD & DRUG L.J. 213, 216-20 (1994).
50. Id. at 218 n.26.
51. Id. at 219.
52. Public Health Service Act, ch. 373, § 351, 58 Stat. 682, 702 (1944)
(current version at 42 U.S.C. § 262 (2000)).
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children contracted polio from a batch of polio vaccine produced
by Cutter laboratories.53 The crisis was attributed to lax
regulation and pressure at NIH to get the vaccine on the
market. One result was the creation of the NIH Division of
Biological Standards (DBS), which Congress transferred to the
FDA in 1972. This unit eventually became the Center for
Biologics Evaluation and Regulation (CBER).
Like the tensions between drug and device regulation,
there were gray areas in the definitional distinctions between
drugs, devices, and biologics. In the 1970s and 1980s, there
was significant innovation in biopharmaceuticals that dissolved
the traditional scientific boundaries among biologics, drugs and
devices. Examples include recombinant insulin, diagnostic
monoclonal antibodies, and interferon.54 As one commentator
noted, “[d]istinguishing the jurisdictional status of many
biologics from traditional drug and device products became
difficult for both the FDA and industry because some products
had characteristics which met multiple statutory and scientific
definitions.”55
By 1980, the FDA had three silos for regulating medical
products- drugs, devices, and biologics. There were gray areas
at the margins. The carefully crafted definitions often did not
fit some innovations or the agency has to stretch its authority
to regulate products.
Inter-center rivalry and cultural
The
traditions influenced the agency’s assessments.56
perception was that CDER played a dominant role among the
Centers and exercised greater influence over the decisions. If a
medical device had drug characteristics, it could get delayed
due to the request for drug expert consultations or subjected to
The
additional, often unexpected regulatory hurdles.57
regulatory process required the manufacturers to navigate
through a maze of definitional and substantive hurdles, with
significant differences in requirements based on how the
product was ultimately classified.

53. HUTT & MERRILL, supra note 13, at 517-18.
54. Gamerman, supra note 49, at 221.
55. Id. at 221 n.53 (citing Assignment of Agency Component for Review of
Premarket Applications, 56 Fed. Reg. 58,754 (codified at 21 C.F.R. pt. 3
(1991))).
56. Kshitij Mohan, Combination Products: Incrementalism Won’t Work,
MED. DEVICE AND DIAGNOSTIC INDUSTRY, May 2002, at 3, available at
http://www.devicelink.com/mddi/archive/02/05/017.html.
57. Id. at 2.
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Before turning our attention to the FDA’s recent
approaches to combination products, it is important to note
that the major legislation on FDA issues in the last twenty
years has not disrupted the three silos created through the
evolutionary process described above. This is true despite
major shifts in the political environment. The Safe Medical
Devices Act of 199058 expanded the FDA’s enforcement and
reporting authority without changing the Center structure.
The FDA Modernization Act, passed after significant attacks on
the FDA’s consumer protection mission by the Republican
Congress in 1995 and 1996, streamlined regulatory processes
without changing the presumptions about the FDA’s
authority.59 Two user fee bills, one for drugs in 1992 (PDUFA),
followed ten years later by one for devices (MDUFMA),
increased the funds available for FDA approvals through
assessments on regulated entities, also without changing the
fundamental regulatory structure.60
At the agency level, this period included continued turf
battles among the three medical products centers. There was a
perception among many that the CDER’s approach dominated
and was treated as superior to the other centers. The 1993
Temple Commission, led by long-time FDA official Dr. Robert
Temple, reported serious reservations about the Device
Center’s scientific capabilities.61 According to FDA expert
Richard A Merrill, the message implicit in Commissioner
Kessler’s decision to authorize an inquiry into the device center
processes was that they were not reliable and its personnel
were not adequately trained.62 In 2003, a shake up at CBER
resulted in the transfer of jurisdiction over a number of
58. Safe Medical Devices Act of 1990, Pub. L. No. 101-629, § 16, 104 Stat.
4511, 4526 (1990) (current version at 21 U.S.C. § 353(g) (2000)).
59. See Larry Pilot & Daniel Waldmann, Food and Drug Administration
Modernization Act of 1997: Medical Device Provisions, 53 FOOD & DRUG L.J.
267, 267, 272-74 (1998).
60. Prescription Drug User Fee Act of 1992 (PDUFA), Pub. L. No. 102571, 106 Stat. 4491 (1992); Medical Device User Fee and Modernization Act of
2002 (MDUFMA), Pub. L. No. 107-250, 116 Stat. 1588 (2002).
61. See U.S. FOOD AND DRUG ADMIN., FINAL REPORT OF THE COMMITTEE
FOR CLINICAL REVIEW: BASED ON A REVIEW OF SELECTED MEDICAL DEVICE
APPLICATIONS, reprinted in SUBCOMM. ON OVERSIGHT AND INVESTIGATIONS OF
THE HOUSE COMM. ON ENERGY AND COMMERCE, LESS THAN THE SUM OF ITS
PARTS: REFORMS NEEDED IN THE ORGANIZATION, MANAGEMENT, AND
RESOURCES OF THE FOOD AND DRUG ADMINISTRATION’S CENTER FOR DEVICES
AND RADIOLOGICAL HEALTH, 103rd Cong., (Comm. Print 1993).
62. Merrill, supra note 44, at 1826.
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biological products from CBER to CDER.63 During this period
of political change, and challenges to the FDA from the left and
the right, the three separate Centers have survived.
III. EVOLUTION OF COMBINATION PRODUCTS
REGULATION
The development of combination products regulation
follows the same iterative and incremental pathway that we
have seen in the areas of drugs, devices, and biologics.
A. SAFE MEDICAL DEVICES ACT INTRODUCES COMBINATION
PRODUCTS
The opportunity to obtain legislative guidance came in
1990 as part of the Safe Medical Devices Act (SMDA). During
the 1980s, following the passage of the complex MDA in 1976,
there was significant concern about the FDA’s implementation
of the law, the challenges built into the law itself, and
limitations on FDA authority in some areas. The General
Accounting Office (GAO) conducted a series of studies on FDA
performance.64 In response, the FDA initiated a multi-phase
Action Plan to improve its timeliness, effectiveness, and
efficiency in drug review, and to improve its medical device
Nevertheless, the drumbeat for legislation
program.65
continued.
The House Subcommittee on Oversight and
Investigations of the Committee on Energy and Commerce
issued a report finding significant failures at the FDA to
implement the law.66 The Department of Health and Human
63. See U.S. FOOD AND DRUG ADMIN. CTR. FOR BIOLOGICS EVALUATION
AND RESEARCH, DEP’T OF HEALTH & HUMAN SERV., TRANSFER OF
THERAPEUTIC PRODUCTS. TO THE CENTER FOR DRUG EVALUATION AND
RESEARCH, at http://www.fda.gov/cber/transfer/transfer.htm (updated Sept.

27, 2004). The report lists the products types to be transferred along with the
staff comprising CBER’s Office of Therapeutics Research and Review which
transferred as well. Id. CDER created two new offices to accommodate the
former CBER staff. See id.
64. See U.S. GEN. ACCOUNTING OFFICE, REPORT TO THE CONG., FED.
REGULATION OF MEDICAL DEVICES -- PROBLEMS STILL TO BE OVERCOME
(GAO/HRD-83-53, 1983); U.S. GEN. ACCOUNTING OFFICE, REPORT TO THE
CHAIRMAN, COMM. ON GOVERNMENTAL AFFAIRS U.S. SENATE, MEDICAL
DEVICES: EARLY WARNING OF PROBLEMS IS HAMPERED BY SEVERE
UNDERREPORTING (GAO/PEMD-87-1, 1986).
65. U.S. FOOD AND DRUG ADMIN., U.S. DEP’T OF HEALTH & HUMAN SERV.,
A PLAN FOR ACTION: PHASE II, at v-vi (1987).
66. HOUSE SUBCOMM. ON OVERSIGHT AND INVESTIGATIONS OF THE COMM.
ON ENERGY AND COMMERCE, 98th Cong., MEDICAL DEVICE REGULATION: THE
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Services (DHHS) developed a draft bill to make the device
provisions more effective in 1985, and House Democrat Henry
Waxman introduced H.R. 5516, Medical Device Improvements
Act, in 1986.67 Waxman also co-sponsored H.R. 2595, Medical
Device Improvements Act, with Energy and Commerce Chair
John Dingell, on June 3, 1987.68 That bill died in the Senate in
1988, and the Safe Medical Devices Act (SMDA) was introduced
on August 2, 1989.69
Combination product issues were not the primary concern
of the House supporters and no provision related to
combinations appeared in the House Report.
However,
industry representatives were able to persuade the Senate
supporters that combination product reviews were a problem
The Senate Report
that needed to be addressed.70
accompanying the bill noted the importance of combination
products, including “devices impregnated with biologicallyactive materials, medicated devices, implantable drug pumps
and biological sensors, and therapeutic devices used in
conjunction with drugs for the extra-corporeal treatment of
diseases.”71 According to the report language, Sections 19 and
20 in the Senate bill established “firm ground rules to direct
products promptly to that part of the FDA responsible for
reviewing the article that provides the primary mode of action
of the combination product.”72 The Senate bill also altered the
definitions of “drug” and “device” to accommodate the principles
of allocation of combination products through primary mode of

FDA’S NEGLECTED CHILD 1-5 (Comm. Print 1983).
67. See Letter from Margaret M. Heckler, Secretary of Health and Human
Services, to the Honorable Thomas P. O’Neill, Speaker of the House of
Representatives (Apr. 17, 1985) (on file with author); H.R. 5516, 99th Cong.
(1986).
68. H.R. 2595, 100th Cong. (1987).
69. After recounting the shortcomings of the FDA, the Honorable Henry
A. Waxman stated “Mr. Speaker, I must note that we should not even be in
the position of introducing further legislation with respect to the regulation of
medical devices. Throughout the last Congress, we worked closely with
representatives of the medical device industry to fashion a compromise bill.”
135 CONG. REC. E 2815 (1989) (statement of Rep. Henry A. Waxman)
(introducing H.R. 3095).
70. “Various persons from industry have expressed the view that a
weakness in FDA’s premarket review process is the determination of how to
regulate combination products.” S. REP. NO. 101-513, at 43 (1990).
71. Id.
72. Id; see also Safe Medical Devices Act of 1990, Pub. L. No. 101-629, §
16, 104 Stat. 4526 (1990) (current version at 21 U.S.C. § 353(g) (2000)).
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action review. The SMDA became law in 1990.73
On November 21, 1991, the FDA published its final
regulation on combination products pursuant to the SMDA.74
The agency also developed inter-center agreements in order to
clarify how the respective centers were to operate in allocating
products based on an assessment of their primary mode of
73. Section 19 amended the drug definition by deleting the words “but
does not include devices or their components, parts, or accessories.” See S.
REP. NO. 101-513, at 43. By deleting this language, a product whose primary
mode of action is attributable to a drug, but has a device component, may be
reviewed under the Act’s drug authority. Id. In addition, the word “primary”
in the device definition was substituted for the word “principal” to conform to
the new concept of primary mode of action. Id. The new legislative language
reads:
(f)(1) The Secretary shall designate a component of the Food and Drug
Administration to regulate products that constitute a combination of
a drug, device, or biological product. The Secretary shall determine
the primary mode of action of the combination product. If the
Secretary determines that the primary mode of action is that of – “(A)
a drug (other than a biological product), the persons charged with
premarket review of drugs shall have primary jurisdiction, (B) a
device, the persons charged with premarket review of devices shall
have primary jurisdiction, or (C) a biological product, the persons
charged with premarket review of biological products shall have
primary jurisdiction. (2) Nothing in this subsection shall prevent the
Secretary from using any agency resources of the Food and Drug
Administration necessary to ensure adequate review of the safety,
effectiveness, or substantial equivalence of an article. (3) The
Secretary shall promulgate regulations to implement market
approval procedures in accordance with paragraphs (1) and (2) not
later than 1 year after the date of enactment of this subsection.
S. REP. NO. 101-959, at 17 (1990).
74. Definition of a Combination Product:
A product comprised of two or more regulated components, i.e.,
drug/device, biologic/device, drug/biologic, or drug/device/biologic, that
are physically, chemically, or otherwise combined or mixed and
produced as single entity; (2) Two or more separate products
packaged together in a single package or as a unit and comprised of
drug and device products, device and biological products, or biological
and drug products; (3) A drug, device, or biological product packaged
separately that according to its investigational plan or proposed
labeling is intended for use only with an approved individually
specified drug, device, or biological product where both are required to
achieve the intended use, indication, or effect and where upon
approval of the proposed product the labeling of the approved product
would need to be changed, e.g., to reflect a change in intended use,
dosage form, strength, route of administration, or significant change
in dose; or (4) Any investigational drug, device, or biological product
packaged separately that according to its proposed labeling is for use
only with another individually specified investigation drug, device, or
biological product where both are required to achieve the intended
use, indication, or effect.
21 C.F.R. § 3.2(e) (2004).
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action.75
The allocation process follows the iterative path we have
described in our discussion of the evolution of drug, device and
biologics previously. In this case, Senate bill recognized the
difficulty of determining the jurisdictional base for regulating
combination products.76 It focused on defining terms and the
allocation process.77 The final bill did not disrupt the three
silos that the Centers represent. Instead, the role of the
allocation process is to establish “firm ground rules” to place a
combination product into one of the three silos.78
Despite the legislative success in the SMDA, innovators in
the field of combination products continued to experience
challenges at the FDA.79 The FDA acknowledged stakeholder
issues including:
concerns about the consistency, predictability, and transparency of
the process used to assign an FDA Center with primary responsibility
for review and regulation . . ., issues related to the management of the
review process when two (or more ) FDA Centers have review
responsibilities for a combination product; lack of clarity about the
postmarket regulatory controls applicable to combination products;
and lack of clarity regarding certain agency policies, such as when
applications to more than one Center are needed.80

Agency efforts did not resolve these issues, leading to
pressure to formalize the allocation process.81 Legislative
authority was sought legislative authority to accomplish the
task.82
The vehicle for this effort was the medical device user fee
legislation that Congress had been considering for years. In
2002, Congress passed the Medical Devices User Fee and

75. See U.S. FOOD AND DRUG ADMIN., INTERCENTER AGREEMENT
BETWEEN THE CENTER FOR DRUG EVALUATION AND RESEARCH AND THE
CENTER FOR DEVICES AND RADIOLOGICAL HEALTH (1991), at
http://www.fda.gov/oc/ombudsman/drug-dev.htm.
76. S. REP. NO. 101-513, at 30 (1990).
77. Id.
78. Id. See Safe Medical Devices Act of 1990, Pub. L. No. 101-629, 104
Stat. 4511 (1990) (current version at 21 U.S.C. § 353(g) (2000)).
79. OFFICE OF COMBINATION PRODS., U.S. FOOD AND DRUG ADMIN., DEP’T
OF HEALTH & HUMAN SERV., ANNUAL REPORT TO CONGRESS: FEDERAL FOOD,
DRUG, AND COSMETIC ACT AS AMENDED BY THE MEDICAL DEVICE USER FEE
AND MODERNIZATION ACT OF 2002, at 4-5 (2003).
80. Id.
81. See id.
82. See id.
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Modernization Act (MDUFMA) of 2002.83 MDUFMA also
amended section 503(g) of the FDCA.84 A provision in the bill
modified definitions to specifically direct assignment to an
agency center pursuant to new procedures.85 These included
the establishment of a new Office of Combination Products
(OCP) within the office of the Commissioner to ensure prompt
assignment and effective review, resolve disputes, and report
on the impact of the office including the numbers and types of
combinations, review times and improvements in consistency.86
With congressional directives in place, the challenge of
combination products was once again in the hands of the
FDA.87
B. PRIMARY MODE OF ACTION
The key challenge was to operationalize SMDA’s “primary
mode of action” language. On May 7, 2004, the FDA issued a
Proposed Rule, “Definition of Primary Mode of Action of a
Combination Product.”88 The proposed rule is “intended to
promote the public health by codifying the agency’s criteria for
the assignment of combination products in transparent,
consistent, and predictable terms.”89 As of this writing, the
proposed rule is still pending.90 Although the rule is not final,
the language of the proposal, as well as the comments from
interested parties, provides insight into the goals of the agency,
and into the views of many drug, device and biologics
manufacturers on this issue.
The FDA notes that “primary mode of action” (PMOA) is
not defined in the statute or regulations, and may be difficult to
identify by either the FDA or the product sponsor at the time
assignment is being considered.91 Accordingly, without clear
83. Medical Device User Fee and Modernization Act of 2002, Pub. L. No.
107-250, 116 Stat. 1588((2002).
84. See id.
85. See id.
86. See 21 U.S.C. §353(g) (2000).
87. Product Jurisdiction, 21 C.F.R. §§ 3.1-3.10 (2003).
88. Definition of Primary Mode of Action of a Combination Product, 69
Fed. Reg. 25,527 (proposed May 7, 2004) (to be codified at 21 C.F.R. pt. 3).
89. Id.
90. The original comment period was to close on July 6, 2004, but was
extended to August 20, 2004. See Definition of Primary Mode of Action of a
Combination Product, 69 Fed. Reg. 35,277 (June 24, 2004).
91. Definition of Primary Mode of Action of a Combination Product, 69
Fed. Reg. at 25,527.
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definitions of “mode of action” and “primary mode of action,”
the assignment process may “appear to be unpredictable.”92
The rule also sets forth a two-tiered assignment algorithm to
use to determine assignment in some circumstances.93 The
proposed rule defines “mode of action” as “the means by which
a product achieves a therapeutic effect” and “primary mode of
action” as “the single mode of action of a combination product
that provides the most important therapeutic action of the
combination product.”94 If the agency cannot determine the
primary mode of action, the assignment algorithm would
apply.95 The next step asks: is there an agency component that
regulates other combination products that present similar
questions of safety and effectiveness with regard to the
combination as a whole?96 If not, the question becomes,
“[w]hich agency component has the most expertise related to
the most significant safety and effectiveness questions
presented by the product?”97
Interested manufacturers, trade associations, and
professional organizations submitted comments to the proposed
rule.98 While most of the comments welcomed the effort and
offered specific responses, a consistent theme emerges. There
is concern, expressed in different ways, that the FDA not
deviate from the terms of the statute (both SMDA and
MDFUMA), and respect prior assignment precedents.99 For
example, the National Electrical Manufacturers Association“
states that:
the proposed rule, with its creation of an algorithm for determination
of the appropriate Center to assign a combination product, would, if
adopted, violate the intent of Congress expressed in MDUFMA by
introducing two criteria for assignment of a combination product
which were not included within the statute when it was enacted.100

92. Id. at 25,528.
93. Id.
94. Id.
95. Id. at 25,529.
96. Id.
97. Definition of Primary Mode of Action of a Combination Product, 69
Fed. Reg. at 25,530.
98. There are twelve posted comments available on the FDA Dockets site.
FOOD AND DRUG ADMIN., COMMENTS ON DEFINITION OF PRIMARY MODE OF
ACTION OF A COMBINATION PRODUCT DOCKET
2004 N-0194, at
http://www.fda.gov/ohrms/dockets/ FDARULE/2004npr.htm#august2004 (last
visited Nov. 7, 2004).
99. Id.
100. Letter from Robert G. Britain, Vice President, Medical Products,
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Smith and Nephew Wound Management expresses concern
about agency discretion: “[w]ithout appropriate statutory
redefinitions, we believe the proposed rule could allow
assignment of jurisdiction of new technologies based solely on
FDA preference particularly where it determines the product
raises new questions of safety and effectiveness.”101 The
comments of Cook, a large holding company of device
manufacturers, urge fidelity to SMDA’s “firm ground rules” for
assignment.102 Cook notes that the agency “must revisit the
law and adjust its proposal to effect the efficient, transparent
and well-defined process that Congress envisioned.”103
These comments imply that the FDA is “stretching” the
scope of its jurisdiction to expand its discretion to assign based
on factors the commentors judge to be inappropriate under the
law. The final rule has not been issued, so it remains to be
seen whether the agency will pursue this arguably broader
interpretation or if it will retreat in a direction the industry
commentors appear to prefer. Whatever the outcome of this
effort, however, the pattern documented here holds. In the
fourteen years since the first statutory reference to combination
products, there have been incremental efforts to respond to new
combinations, legislative redefinition of terms, and new
procedural directions, and now challenges to the agency’s
interpretation of its authority.
IV. POLICY ANALYSIS
Combination products continue to present challenges to the
regulatory structure of the FDA. How to regulate innovative
combinations raises issues that are similar to those that arose
National Electrical Manufacturers Association, to Food and Drug
Administration, Division of Documents Management, Re: Docket No 2004N0194
(Aug.
17,
2004),
at
http://www.fda.gov/ohrms/dockets/dailys/04/aug04/082304/04N-0194emc00002-01.pdf (last visited Apr. 19, 2005).
101. Letter from Ronald S. Warren, Executive Director, Smith & Nephew
Wound Management, to Food and Drug Administration, Division of Dockets
Management, Re: Docket No. 2004N-0194 (Aug. 18, 2004), at
http://www.fda.gov/ohrms/dockets/dailys/04/aug04/082404/04n-0194-c00009vol1.pdf (last visited Apr. 19, 2005).
102. Letter from Stephen L. Ferguson, Executive Vice President and
Chairman of the Board, Cook Group, Inc., to Food and Drug Administration,
Division of Dockets Management, Re: Docket No. 2004N-0194 (Aug. 20, 2004),
at http://www.fda.gov/ohrms/dockets/dailys/04/aug04/082404/04n-0194-c00005vol1.pdf (last visited Apr. 19, 2005).
103. Id.
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around the emergence of innovative drugs, devices, and
biologics in the last century. The public policy response to
combination products to date has followed predictable patterns.
Congress defines the new product and sets specific structures
and pathways for the FDA to implement. The FDA interprets
its authority, designs regulatory guidelines, through rules,
guidances, and other directives. The process is clearly reactive
to innovation. It is incremental in approach, focusing on
problems that have been identified and experienced, rather
than proactive and broad. It is slow by nature. It has been
fourteen years since Congress first defined combination
products. Since that time, there have been two legislative
initiatives and a host of regulatory responses. The rule
defining a PMOA is pending. New guidances have recently
been issued. Some in industry have called for a re-definition of
terms. The process continues.
While the process has been incremental, reactive, and slow,
it also has merit in that it is generally predictable. Regulated
entities whose efforts to develop new products span years and
constitute large investments value predictability in the
regulatory process.
While the numbers of combination
products have remained manageable,104 it is possible that an
onslaught of unique and novel combinations will further
challenge the current regulatory scheme. Can the current
regulatory process withstand these forces? What are the policy
alternatives?
A. STATUS QUO APPROACH
The status quo approach involves accepting the traditional
historical pattern. One can predict that the FDA will labor to
provide guidance on implementation based on what is currently
known about combinations. It may try to “stretch” its authority
to adapt to uncertainties in the future, such as the effort to
design an algorithm for products for which the primary mode of
action is not known. Turf battles among the centers will
continue. But it is likely that new products will emerge that do
not fit the current structure and will challenge the OCP’s
efforts. At that point, expect industry to go back to the
Congressional drawing board, so to speak, to urge a legislative
tweak of the definitions and further refine the terms. If the
innovative process accelerates the way some predict, this policy
104. See OFFICE OF COMBINATION PRODS., supra note 12.
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cycle will always be behind the innovation curve. As Dr.
Kshitij Mohan, a former FDA official and industry executive
noted,
Much of this effort is like measuring length to the fourth decimal
place with a crooked ruler. The danger is that the traditional way of
dealing with such complexity will make the process even more
complex. A new maze of regulations, guidelines, and guidance memos
could be the result.105

B. ALTERNATIVE APPROACHES TO THE STATUS QUO
One alternative to the status quo is to declare that all
combination products will follow the regulatory pathway of one
of three existing centers. Some medical device innovators have
suggested a presumption in favor of the device laws, which they
argue are more flexible and adaptable than those that apply to
drugs or biologics. Drug or biological expertise could be
acquired or imported to CDRH as needed. This solution retains
the three centers and allows firm ground rules and
predictability by applying one center’s jurisdiction. However,
given the history of inter-center rivalry, the perception that
drug regulation is more protective and CDER has more
expertise, and the fact that many combinations are primarily
drugs or biologics, there is likely to be resistance to this
alternative within the agency and among drug and biologic
firms.
Another alternative is to abandon the effort to shoehorn
innovations into one of the three silos, pursuant to the SMDA
and MDUFMA directives, and create a new Center for
Combination Products. This may be a natural extension of the
historical pattern and, indeed, new types of products did find
their way into new centers over time. Creating a new center
would require legislative action.
There would be new
challenges to overcome with this approach. Deciding what
would be the appropriate regulatory pathway would still
involve choosing attributes from the various product-specific
centers and borrowing or acquiring a broad range of expertise,
much of it located elsewhere. Combinations are not as tidily
discrete as drugs, devices or biologics. A fourth silo could
complicate the process and undermine efforts at predictability.
It could also exacerbate the legislative “crazy quilt” with “a
bounty of approaches, with each patch of authority a little, or a

105. Mohan, supra note 56, at 2-3.
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lot, different from the others.”106
C. ABANDON THE CENTERS CONCEPT
A bolder and clearly controversial step would be to
abandon the complex “crazy quilt” of three centers and move to
a more flexible approach. This “innovative” approach would
allow for adaptation to new products in creative ways. This
approach would require a major sea change in the historical
relationship of the institutions of government and with the
regulated entities.
Congress has traditionally limited FDA discretion through
very specific and detailed legislative mandates. The FDA often
has been under fire with Congress, although the fire varies
depending on the politics of the time. During the debates over
the SMDA in the 1980s, former Democratic Congressman Paul
Rogers wrote:
[t]he philosophy behind the writing of the Medical Device
Amendments was to be so specific in language that less discretion
was left to the agency—a first step in the trend in the Congress to
make clear that Congress wanted the agencies to follow the
Congressional mandate more carefully and not go off on bureaucratic
binges pursuing bureaucratic whims.107

During the debates over FDAMA in the 1990s, the
Republican majority criticized the FDA for not responding more
vigorously to industry needs.108 At various times, both parties
have been inclined to distrust agency discretion and guide the
FDA with specific and highly detailed legislation. In 2004,
Senate Republican Finance Committee Chairman Charles
Grassley called for hearings to determine if the FDA was too
lax in its oversight of Merck’s drug Vioxx. 109 This is an
example of a Republican leader calling the agency to account
for alleged laxity in regulatory oversight.
The manufacturers of medical products have not shown an
inclination to support agency discretion either.
If the
comments filed in response to the proposed PMOA rule are any
indication, yearnings for flexibility are offset by distrust of the

106. Horton, supra note 14, at 546.
107. Paul G. Rogers, Medical Device Law — Intent and Implementation, 36
FOOD DRUG COSM. L.J. 4, 4 (1981).
108. See Peter H. Stone, Ganging Up on the FDA, NAT’L J., Feb. 18, 1995,
at 410.
109. Merck Chief is Asked to Testify, NEW YORK TIMES, Nov. 11, 2004, at
C5.
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agency’s exercise of discretion. As we discussed earlier, many
of the industry comments specifically took the FDA to task for
broadly construing its own authority.110
Will the FDA press for more discretion? The FDA is a
creature of Congress and subject to its oversight. Exercise of
discretion can be risky; caution may be its preferred state. On
occasion, FDA commissioners have taken risks. Commissioner
David Kessler aggressively interpreted FDA authority to
regulate tobacco as a drug (and cigarettes as drug delivery
devices) during his tenure.111 He boldly set out to do so and
enacted a rule asserting authority to regulate tobacco.112 The
tobacco industry challenged his efforts as outside the scope of
the FDA’s authority and on other grounds.113 The U.S.
Supreme Court upheld the industry’s challenge and the rule
was struck down.114
The courts have upheld broad FDA discretion, but only
when Congress has been silent or ambiguous.115 Jeffrey E.
Shuren, a former FDA official, has forcefully argued for broad
FDA discretion.116 He contends that “courts should grant
sufficient deference to agencies’ modifications of prior statutory
interpretations in order to ensure adequate agency flexibility to
meet new challenges within existing statutory delegations of
authority.”117
Congress is not likely to confer broad discretion. Even
conservatives and liberals have shown distrust of the FDA. It
would take a very creative Congress, supported by a willing
industry, and backed by generous judicial interpretations, to
change the course of the FDA’s history. There is no evidence in
110. See supra note 98.
111. See Regulations Restricting the Sale and Distribution of Cigarettes
and Smokeless Tobacco Products to Protect Children and Adolescents, 60 Fed.
Reg. 41,314 (proposed Aug. 11, 1995).
112. See Regulations Restricting the Sale and Distribution of Cigarettes
and Smokeless Tobacco Products to Protect Children and Adolescents, 61 Fed.
Reg. 44,396, 44,400 (Aug. 28, 1996).
113. See Coyne Behm, Inc. v. United States Food and Drug. Admin, 966 F.
Supp. 1374 (M.D.N.C. 1997).
114. United States Food and Drug Admin. v. Brown & Williamson Tobacco
Corp., 529 U.S. 120 (2000).
115. Chevron, U.S.A., Inc. v. Natural Res. Def. Council, Inc., 467 U.S. 837,
866 (1984).
116. See Jeffrey E. Shuren, The Modern Regulatory Administrative State:
A Response to Changing Circumstances, 38 HARV. J. ON LEGIS. 291, 292
(2001).
117. Id.
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the past or present to make this option likely.
CONCLUSION
At the outset, we asked: “Can Regulation be as Innovative
as Science and Technology?” The answer to the question is no.
There appears to be little appetite to confer upon the FDA the
discretion and flexibility to respond creatively to combination
products, or other novel and as yet unforeseen innovations in
the future. The history of the FDA is one of iterative,
incremental changes through carefully defined legislative
distinctions and highly specific regulatory pathways. Politics
and administrative law are likely to prevent the FDA from
being a bold innovator.
One could argue, however, that our system does not favor
innovation in regulatory agencies, even as it is embraced in our
scientists and engineers. Innovators and the manufacturers of
innovations want regulatory predictability and certainty. They
appear to be willing to sacrifice speed and flexibility in
exchange. Given the nature of our policy environment and our
political preferences, regulators will surely follow the scientific
innovators, not lead them.

